findmyKOL

Shilpi Singh, MD, MPH

Basic profile

Endocrinology, Diabetes & Metabolism

ORCIDNPI
RegionJamesburg, NJ · NortheastSpecialtyEndocrinology, Diabetes & MetabolismFocusEndocrinology/Metabolic
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2025Online presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Shilpi Singh is an Endocrinology/Metabolic physician. OpenAlex indexes 55 publications with 2,326 citations (h-index 22).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
55publications

Distinct works indexed by OpenAlex, matched via ORCID.

2,326citations

Total citations across indexed works.

22h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
36companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

100 Lakeview Dr Ste 2
Jamesburg, NJ 088312601

Telephone

402-280-2010

Provider last certified this registry record 30 Apr 2025.

View the NPPES registry record

Industry payments

36 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Metabolism & gastrointestinal

    57.8%
    GLP-1 receptor agonist14.3%
    Ozempic56%Mounjaro21%Trulicity16%Rybelsus7%
    Part D109 patients
    Insulin Analog13.2%
    Lantus Solostar23%Humalog Kwikpen U-10015%Novolog Flexpen11%Basaglar Kwikpen U-1009%Tresiba Flextouch U-2009%Humalog6%Toujeo Solostar6%Insulin Lispro Kwikpen U-1005%Toujeo Max Solostar5%Fiasp Flextouch3%Novolog3%Tresiba Flextouch U-1003%Lyumjev Kwikpen U-1002%
    Part D<11 patients

    + 9 more classes in this area

  • Hormonal (systemic)

    21.2%
    l-Thyroxine17.4%
    Levothyroxine Sodium75%Synthroid19%Unithroid5%Levoxyl1%
    Part D<11 patients
    Thyroid Hormone Synthesis Inhibitor1.2%
    Methimazole100%
    Part D27 patients

    + 6 more classes in this area

  • Cardiovascular

    17.6%
    Statin9.4%
    Atorvastatin Calcium45%Rosuvastatin Calcium37%Simvastatin12%Pravastatin Sodium7%
    Part D<11 patients
    Angiotensin receptor blocker (ARB)2.2%
    Losartan Potassium80%Losartan-Hydrochlorothiazide12%Olmesartan Medoxomil9%
    Part D<11 patients

    + 7 more classes in this area

Where care is delivered (Part B)47.2% facility · 52.8% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”